Skip to main content
main-content

Zeitschrift

Targeted Oncology

Targeted Oncology OnlineFirst articles

12.12.2018 | Original Research Article Open Access

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib

For patients with advanced non-small-cell lung cancer (NSCLC) and activating epidermal growth factor receptor ( EGFR ) mutations, EGFR tyrosine kinase inhibitors (TKIs) are standard first-line treatment [ 1 ]. First- (gefitinib, erlotinib), second- …

07.12.2018 | Review Article

Therapy of Advanced Prostate Cancer: Targeting the Androgen Receptor Axis in Earlier Lines of Treatment

With the decrease in PSA screening based on the 2011 United States Preventive Services Task Force guidelines and the potential approval of highly sensitive imaging techniques over the next few years, we are likely to see an increasing trend of …

05.12.2018 | Original Research Article Open Access

PD-1 and PD-L1 Expression in Male Breast Cancer in Comparison with Female Breast Cancer

Male breast cancer is rare and represents less than 1% of all breast cancer cases. Consequently, less is known about men with breast cancer compared to women with breast cancer. Generally, male breast cancer has a more advanced stage, a lower …

28.11.2018 | Original Research Article

Gemcitabine Combined with the mTOR Inhibitor Temsirolimus in Patients with Locally Advanced or Metastatic Pancreatic Cancer. A Hellenic Cooperative Oncology Group Phase I/II Study

Pancreatic cancer is one of the most lethal human diseases. It is the fourth leading cause of cancer-related death among men and women in the United States. Most patients present with advanced disease and their prognosis is dismal [ 1 ]. Even for …

23.11.2018 | Review Article

New Horizons in the Treatment of Metastatic Pancreatic Cancer: A Review of the Key Biology Features and the Most Recent Advances to Treat Metastatic Pancreatic Cancer

Only a limited number of therapeutic strategies are available for patients diagnosed with pancreatic adenocarcinoma, and disease recurrence and mortality are consequently high. For metastatic disease, two combinations are approved in the first …

Aktuelle Ausgaben

Weitere Informationen

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise